Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2012. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMR), or Connected Persons, specifically regarding shareholdings within the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific shareholding notification and does not contain general financial performance data.
Material Changes
A revaluation of the cash element of the notional investment held within the US Retirement Savings Plan resulted in an increase in the notional allocation of American Depositary Shares (ADSs). The transaction occurred on June 22, 2012, at a price of $45.89 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It strictly reports a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Type: Notional increase in ADS allocation due to plan revaluation.
- Price: $45.89 per ADS.
- Directors Involved: Dr. M M Slaoui (0 ADSs allocated in this specific notification).
- Connected Persons Involved: Dr. K Slaoui (4 ADSs allocated).
- Reporting Date: June 25, 2012.